DATATRAK Exhibiting at 47th Annual DIA Meeting

CLEVELAND, June 13, 2011 /PRNewswire/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced its attendance at the Drug Information Association's (DIA) 47th Annual Meeting, which will be held in Chicago, Illinois June 19th-23rd.

DATATRAK will be exhibiting at the island booth #735 on June 20th-22nd. Individuals attending the meeting are invited to the booth to view demonstrations of the latest DATATRAK ONE™ unified product suite. Attendees can use this opportunity to learn more about the 'u'!   Come find out how DATATRAK can accelerate your drug delivery timelines.

In addition, DATATRAK experts will be participating in the following sessions:

On Wednesday, June 22nd, DATATRAK's Director of Quality Assurance, Shiela McLaughlin will present A Risk-Based Approach to Vendor Management during track 9A's Regulatory Affairs and Science, Quality and GXP Compliance session.

On Thursday, June 23rd, DATATRAK's Director of Client Services and Internal Operations, Kathy Tibaldi will chair the 9AM session titled Training: Hot Issues of Track 15's Professional Development and Training.

About 47th Annual DIA Meeting

The DIA Annual Meeting is the premier event for professionals involved in the discovery, development and lifecycle management of pharmaceuticals, medical devices and related products. There is no other industry meeting of its kind that can rival the breadth and depth of experience that this meeting delivers. For more information, please see www.diahome.org.

About DATATRAK International, Inc.

DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services™ group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK eClinical® software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I – Phase IV drug and devices studies in multiple languages throughout the world. DATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain of the factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's quarterly report filed with the OTCQX Market announcing its results for the three-month period ending March 31, 2011. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE DATATRAK International, Inc.

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.